Kathleen P. Gallagher - Jan 6, 2025 Form 3 Insider Report for Avidity Biosciences, Inc. (RNA)

Role: Chief Program Officer
Signature: /s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact
Stock symbol: RNA
Transactions as of: Jan 6, 2025
Transactions value $: $0
Form type: 3
Date filed: 1/8/2025, 06:52 PM
Next filing: Jan 23, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	RNA	Common Stock						35K	Jan 6, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	RNA	Stock Option (Right to Buy)							Jan 6, 2025	Common Stock	22.3K	$25.12	Direct	F2
holding	RNA	Stock Option (Right to Buy)							Jan 6, 2025	Common Stock	1K	$22.56	Direct	F3
holding	RNA	Stock Option (Right to Buy)							Jan 6, 2025	Common Stock	25.3K	$14.70	Direct	F4
holding	RNA	Stock Option (Right to Buy)							Jan 6, 2025	Common Stock	40.6K	$16.65	Direct	F5
holding	RNA	Stock Option (Right to Buy)							Jan 6, 2025	Common Stock	27.6K	$22.47	Direct	F6
holding	RNA	Stock Option (Right to Buy)							Jan 6, 2025	Common Stock	1K	$8.82	Direct	F3
holding	RNA	Stock Option (Right to Buy)							Jan 6, 2025	Common Stock	42.5K	$8.24	Direct	F7
holding	RNA	Stock Option (Right to Buy)							Jan 6, 2025	Common Stock	13.5K	$10.16	Direct	F8
holding	RNA	Stock Option (Right to Buy)							Jan 6, 2025	Common Stock	16K	$44.00	Direct	F9

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest as follows: 1,991 RSUs on each of the first four anniversaries of January 20, 2023; 6,125 RSUs on each of the first four anniversaries of January 20, 2024; and 625 RSUs on each of the first four anniversaries of August 30, 2024, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
F2	This option was granted on April 26, 2021 and vests in equal installments of 2,029 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on April 26, 2025.
F3	This option is fully vested and exercisable as of the date hereof.
F4	This option was granted on January 20, 2022 and vests in equal installments of 1,383 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2026.
F5	This option was granted on July 18, 2022 and vests in equal installments of 553 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on July 18, 2026.
F6	This option was granted on January 20, 2023 and vests in equal installments of 774 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2027.
F7	This option was granted on August 20, 2023 and vests in equal installments of 885 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on August 20, 2027.
F8	This option was granted on January 20, 2024 and vests in equal installments of 282 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2028.
F9	This option was granted on August 30, 2024 and vests in equal installments of 333 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on August 30, 2028.